Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics - PubMed (original) (raw)
Randomized Controlled Trial
Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics
Damaris J Rohsenow et al. Exp Clin Psychopharmacol. 2007 Jun.
Abstract
Naltrexone's (NAL) effects on alcohol consumption are generally modest, so identifying patients likely to benefit would improve treatment utility. Several studies indicate that potentially significant moderators of NAL's effects might include family history of alcohol problems (FH), age of onset of alcohol problems, degree of antisocial traits, and comorbid drug use. Data from 128 alcoholic patients enrolled in a 12-week NAL treatment study (50 mg/day) were reanalyzed to determine the role of FH, age of onset, antisocial traits, and comorbid drug use in NAL's treatment effects on heavy drinking days. Dichotomized FH, age of onset of alcohol problems, and comorbid cocaine or marijuana use had no interaction effect with medication. Percentage of relatives with problem drinking (family history percentage [FHP]) moderated the effects of NAL on drinking such that NAL resulted in lower drinking rates only for patients with higher FHP. Antisocial traits also moderated the effects of medication on drinking for patients compliant with =70% of medication. Patients with more antisocial traits had less heavy drinking on NAL than on placebo, whereas patients low on antisocial traits had no benefit from NAL. Covarying antisociality in regressions of drinking outcome on FHP showed that the effects of FHP were not attributable to antisociality. Thus, NAL may selectively benefit alcoholics with antisocial traits or 20% or more relatives with problem drinking.
(c) 2007 APA, all rights reserved
Similar articles
- Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA. Tidey JW, et al. Alcohol Clin Exp Res. 2008 Jan;32(1):58-66. doi: 10.1111/j.1530-0277.2007.00545.x. Epub 2007 Nov 20. Alcohol Clin Exp Res. 2008. PMID: 18028530 Free PMC article. - The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. Pettinati HM, et al. J Clin Psychopharmacol. 2006 Dec;26(6):610-25. doi: 10.1097/01.jcp.0000245566.52401.20. J Clin Psychopharmacol. 2006. PMID: 17110818 Review. - Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C, Kahler CW, Swift RM, O'Malley SS. Capone C, et al. J Stud Alcohol Drugs. 2011 Jan;72(1):135-40. doi: 10.15288/jsad.2011.72.135. J Stud Alcohol Drugs. 2011. PMID: 21138720 Clinical Trial. - Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. McGeary JE, et al. Alcohol Clin Exp Res. 2006 Aug;30(8):1288-96. doi: 10.1111/j.1530-0277.2006.00156.x. Alcohol Clin Exp Res. 2006. PMID: 16899031 Clinical Trial. - Pharmacogenomics of alcohol response and addiction.
Enoch MA. Enoch MA. Am J Pharmacogenomics. 2003;3(4):217-32. doi: 10.2165/00129785-200303040-00001. Am J Pharmacogenomics. 2003. PMID: 12930156 Review.
Cited by
- Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.
Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, Leggio L. Kenna GA, et al. Addict Biol. 2016 Jul;21(4):904-14. doi: 10.1111/adb.12275. Epub 2015 Jun 2. Addict Biol. 2016. PMID: 26037245 Free PMC article. Clinical Trial. - Effects of naltrexone on cortisol levels in heavy drinkers.
Ray LA, Mackillop J, Leggio L, Morgan M, Hutchison KE. Ray LA, et al. Pharmacol Biochem Behav. 2009 Feb;91(4):489-94. doi: 10.1016/j.pbb.2008.09.004. Epub 2008 Sep 13. Pharmacol Biochem Behav. 2009. PMID: 18824022 Free PMC article. - Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving.
de Laat B, Nabulsi N, Huang Y, O'Malley SS, Froehlich JC, Morris ED, Krishnan-Sarin S. de Laat B, et al. Mol Psychiatry. 2021 Sep;26(9):5053-5060. doi: 10.1038/s41380-020-0811-8. Epub 2020 Jun 15. Mol Psychiatry. 2021. PMID: 32541931 Free PMC article. - Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence.
Garbutt JC, Osborne M, Gallop R, Barkenbus J, Grace K, Cody M, Flannery B, Kampov-Polevoy AB. Garbutt JC, et al. Alcohol Alcohol. 2009 May-Jun;44(3):293-300. doi: 10.1093/alcalc/agn122. Epub 2009 Feb 3. Alcohol Alcohol. 2009. PMID: 19189996 Free PMC article. Clinical Trial. - Effects of alcoholism typology on response to naltrexone in the COMBINE study.
Bogenschutz MP, Scott Tonigan J, Pettinati HM. Bogenschutz MP, et al. Alcohol Clin Exp Res. 2009 Jan;33(1):10-8. doi: 10.1111/j.1530-0277.2008.00804.x. Epub 2008 Sep 30. Alcohol Clin Exp Res. 2009. PMID: 18828797 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
- 2R01 AA07850/AA/NIAAA NIH HHS/United States
- T32 AA07459/AA/NIAAA NIH HHS/United States
- K23 AA014966/AA/NIAAA NIH HHS/United States
- 1 R01 AA013880-04/AA/NIAAA NIH HHS/United States
- 1K23 AA014966/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous